Moon Surgical Scopilot
Authors: Katerina Jou, MD, David Pechman, MD
Moon Surgical, a French-American surgical technology-focused company, received FDA clearance for ScoPilot™ on March 18, 2025.
ScoPilot™ is the first intraoperative artificial intelligence platform that enables NVIDIA’s Holoscan to run locally on Moon Surgical’s Maestro™ system, the company’s robotic surgical assistant that received FDA clearance in June 2024. ScoPilot™ aims to provide intelligent laparoscope control using computer vision-based capabilities. As a result, the surgeon will not need to take their hands off utilized surgical instruments to adjust their field of view. ScoPilot™ utilizes artificial intelligence to anticipate a surgeon’s actions and to adjust the camera position based on the anticipated instrument motion to optimize surgical flow and efficiency with its augmented sensor processing. According to Moon Surgical, while paired with NVIDIA computing and AI software, ScoPilot™ will be able to generate a dataset centered around understanding and identifying interventions for perioperative workflow with its ambient sensing and kinematics capture.
The ScoPilot™ feature reduces operative timing with the goal of enabling more solo surgeries to be performed and in turn reduced physical strain and improvement in surgical ergonomics. It has been successfully applied to the Moon Surgical Maestro™ system with cholecystectomy thus far.
The device was determined to be substantially equivalent to the predicate devices: Maestro System, Moon Surgical SAS (K240598) Autolap System, Medical Surgery Technologies, Ltd. (K152848).
Currently, ScoPilot™ has been used by ten surgeons in two hospitals in France. It has not yet been announced when ScoPilot™ will be fully integrated with Moon Surgical’s Maestro™ system.
Sources:
https://websurg.com/tw/doi/vd01en7331
https://www.linkedin.com/feed/update/urn:li:activity:7307882873347350528